Associate Professor

Inmaculada Hernandez Photo
Inmaculada Hernandez, PharmD, PhD

Associate Professor, Division of Clinical Pharmacy

Skaggs School of Pharmacy and Pharmaceutical Sciences

(858) 822-6047
Research Summary

Dr. Hernandez’s research has focused on evaluating clinical outcomes of oral anticoagulants and studying pharmaceutical pricing. She has published in top-tier journals, including JAMA, Annals of Internal Medicine, JAMA Internal Medicine, and Health Affairs. Her research has been featured in the main media outlets, including New York Times, Washington Post, NPR, CNN, Forbes, BBC, ABC, CNBC, or Bloomberg. In 2018, she was recognized on the Forbes 30 under 30 list as a young leader in healthcare research.

Academic Achievements

Education: PharmD (2013) University of Navarra (Spain); Master of Science in Health Economics and Pharmacoeconomics (2013) University Pompeu i Fabra (Spain); PhD in Health Services Research and Poilicy (2016) University of Pittsburgh.

Awards and Honors: Seema S. Sonnad Emerging Leader in Managed Care Research Award (2019); Fellow, American Heart Association (2019); Delta Omega Public Health Honor Society Inductee (2019); Rho Chi Society Outstanding Scholarly Contribution Award (2019); Forbes 30 under 30 (2018); Fellow, American College of Cardiology (2018); Delta Omega National Public Health Honor Society Omicron Chapter Best Doctoral Dissertation Award (2017); PCORI/AHA Comparative Effectiveness Research and Precision Medicine Approaches for Heart Disease and Stroke Treatment Research Clinician Challenge Award (2016).

  • Introduction to Health Care Systems and Policy.
Key Contributions
  • First nation-wide study quantifying access to potential COVID-19 administration facilities
  • First estimation of the effect of rising manufacturer discounts in offsetting increases in list prices of drugs (Hernandez et al. JAMA 2020)
  • First validation of SSR Health Data in drug pricing research (Hernandez et al. JAMA 2020)
  • First publication demonstrating to what extent rising drug prices are due to innovation versus inflation (Hernandez et al. Health Affairs 2019)
  • First report demonstrating changes in prices of drugs under shortages (Hernandez et al. Ann Intern Med 2019)
  • First evidence on outcomes associated with the resumption of direct oral anticoagulants in patients surviving a major bleeding event (Hernandez et al. Stroke 2018)
  • First estimation of the risk of bleeding with dabigatran in the real-world clinical practice (Hernandez et al. JAMA Intern Med 2015)
  • Development of Fellowship in Pharmaceutical Outcomes Research and Pharmacoeconomics
Potential Collaborative Programs
  • Health economics and outcomes research studies     of anticoagulants.
  • Evaluation of new insurance programs and provider payment models.